RT Journal Article
SR Electronic
T1 The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267605
DO 10.1101/2021.12.15.21267605
A1 Benschop, Robert J.
A1 Tuttle, Jay L.
A1 Zhang, Lin
A1 Poorbaugh, Josh
A1 Kallewaard, Nicole L.
A1 Vaillancourt, Peter
A1 Crisp, Melissa
A1 Vy Trinh, Thi Ngoc
A1 Freitas, Joshua J.
A1 Beasley, Stephanie
A1 Daniels, Montanea
A1 Haustrup, Natalie
A1 Higgs, Richard E.
A1 Nirula, Ajay
A1 Cohen, Myron S.
A1 Marovich, Mary
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267605.abstract
AB As the COVID-19 pandemic evolves, and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of SARS-CoV-2 infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of six months, serum samples were collected from the prevention population (nursing home residents and staff) enrolled in the BLAZE-2 clinical trial who had received either bamlanivimab (4200 mg) or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines, as part of the US vaccination program. This post-hoc analysis assessed the immune response to vaccination for the subset of participants (N=135) without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not significantly bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo participants mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk-category and vaccine type, with any observed differences unlikely to be clinically meaningful. These findings are pertinent for informing public health policy with results that suggest a complementary role for COVID-19 monoclonal antibodies (mAbs) with COVID-19 vaccines and that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 mAb infusion.One Sentence Summary Individuals infused with an anti-SARS-CoV-2 antibody demonstrated a robust immune response to subsequent full COVID-19 vaccination.Competing Interest StatementThis work was supported by Eli Lilly and Company. RJB, JLT, LZ, NLK, JP, SB, TNVT, MC, JJF, MD PV, LZ, REH and AN are all employees and stockholders of Eli Lilly and Company. NH is an employee of Eli Lilly and Company. MSC declared study funding by National Institute of Health (NIH), consulting fees from Lineage Logistics and Atea Pharmaceutical, payment for educational events from NY Course, Magen, MJH Life Sciences, Clinical Care solutions and Virology Education, support for attending advisory meetings from Krog Healthcare; GlaxoSmithKline (GSK), Trinity Health Sciences and GSK, leadership or fiduciary roles at HPTN, CoVPN, Fogarty and McGill.Clinical Protocols https://jamanetwork.com/journals/jama/fullarticle/2780870 Funding StatementThis study was funded by Eli Lilly and Company.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Advarra gave ethical approval for the entire BLAZE-2 study on July 2020 and all institutional review boards also provided ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript